Science spotlight: Doudna lab’s cell-penetrating CRISPR RNPs, durable epigenome editing and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Senior Biopharma Analyst

March 2, 2024 12:56 AM UTC

A peptide-based strategy for enhancing cellular uptake of a non-viral CRISPR system could enable in vivo use of more precise and less immunogenic genome editors.

CRISPR ribonucleoprotein (RNP) genome editors’ advantages over virally delivered CRISPR machinery include reduced off-target and immunogenic effects. The RNP carries the Cas protein and guide RNA directly, without relying on a delivery vector, but its ability to enter cells is limited.